2001, Number 4
<< Back Next >>
Rev ADM 2001; 58 (4)
Influence of time under antiretroviral therapy highly active over oral lesions associated to HIV infection
Ceballos SA, Gaitán CLA, Ceballos GL
Language: Spanish
References: 24
Page: 123-129
PDF size: 192.35 Kb.
ABSTRACT
Objective: To establish if the time under antiretroviral therapy highly active (TAAA), including inhibitors of protease of HIV-1 has an influence in the prevalecence of oral lesions associated to infection from HIV (OL-HIV).
Material and methods: 412 patients HIV+/AIDS under TAAA (patients under TAAA between 24-28 weeks; and patients under TAAA ≥ 104 weeks), 304 males, 108 females from the Hospital Regional de Málaga “Carlos Haya” were examined and was established the prevalecence of oral lesions associated to infection from HIV. It was considered as deep immunosupression the count of limphocite CD4 + ‹ 200/mL and/or 10,000 copies/‹L. Comparison of the prevalecence in both groups with the Chi square and exact Fisher’s. Establishing odds ratio for OL-HIV.
Results: The highest prevalecence of OL-HIV, oral candida and lukoplakia vellosa were found in the group under 104 weeks of TAAA and in the patients with high virus charges. Conclusions: The time under active TAAA does not influence the prevalecence of oral lesions, nor the probability to have or not oral lesions associated to infection with HIV.
REFERENCES
Scully C, Laskaris G, Pindborg J, Porter SR, Reichert P. Oral manifestations of HIV infection and their management. I. More common lesions. Oral Surg Oral Med Oral Pathol 1991; 71: 158-66.
Glick M, Muzyka BC, Lurie D, Salkin L. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994; 77: 344-349.
Patton LL, Mckaig R, Strauss R, Rogers D, Eron JJ. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol 2000; 89: 299-304.
Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
Margiotta V, Campisi G, Mancuso S, Accurso V, Abadessa V. HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population. J Oral Pathol Med 1999; 28: 173-7.
Mallolas J, Arrizabalaga J, Loncha M, Gatell JM, Adán A, Martínez-Chamorro E et al. Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors. AIODS 1997; 11(14): 1784-1786.
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Furher J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Medicine 1998; 338(13): 853-860.
Pezzotti P, Napoli PA, Acciai S, Boros S, Urciuoli, Lazzeri V et al. Increasing survival time after AIDS in Italy: the role of new combination antirretroviral therapies. AIDS 1999; 13: 249-255.
Currier JS. Opportunistic infections in the age of highly active antiretroviral therapy. AIDS Patient Care and STDs 1998; 12(7): 521-524.
Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 Protease inhibitors. A review for clinicians. JAMA 1997; 277(2): 145-153.
Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A et al. Role of portease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. JAIDS 1999; 21: 20-25.
Diz Dios P, Ocampo A, Miralles C, Otero I, Iglesias I, Rayo N. Frequency of oropharyngeal candidiasis in HIV-infected patients on portease inhibitor therapy. Oral Surg Oral Med Oral Pathol 1999; 87(4): 437-441.
EC-Clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus: Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993; 22: 289-91.
Holmstrup P, Axel T. Classification and clinical manifestation of oral yeasts infections. Acta Odont Scand 1990; 48: 57-61.
Ceballos A, Gaitán L, Ceballos L. Oral lesions in HIV+/AIDS patients under highly active antiretroviral virus. AIDS Patient Care and STDs. In press.
Hoegl L, Thoma-Greber E, Rocken M, Korting HC. Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor. Mycoses 1998; 41(5-6): 213-7.
Ceballos A, Aguirre JM, Bagán JV. Oral manifestation associated with human immunodeficiency virus infection in a Spanish population. J Oral Pathol Med 1996; 25: 523-6.
Laskaris G, Hadjivassiliou M, Stratigos J. Oral signs and symptoms in 160 Greek HIV infected patients. J Oral Pathol Med 1992; 21: 120-31.
Revankar SG, Sanche SE, Dib, Caceres M, Patterson. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998; 12(18): 2511-2513.
Chougnet C, Fowke KR, Mueller BU, Smith S, Zuckerman J, Jankelevitch S et al. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. AIDS 1998; 12: 2397-2406.
Ficarra G, Shillitoe EJ, Adler-Storthz K, Gaglioti D, Di Pietro M, Riccardi R. Oral melanotic macules in patients infected with human immunodeficiency virus. Oral Surg Oral Med Oral Pathol 1990; 70: 748-55.
Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. “Bufalo hump” in men with HIV-1 infection. Lancet 1998; 351: 867-870.
Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Fallon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-875.
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users. JAMA 1998; 279(1): 35-40.
Full text